Evidence-based R&D
A data-driven approach to every design decision. More than 100 preclinical heart perfusions and counting — the science leads the product, not the other way around.
About Vascular Perfusion Solutions
A Texas MedTech company built on scientific integrity.
We advance cardiac graft preservation through simplified hypothermic machine perfusion — working closely with leading scientists, engineers, and clinical advisors to rigorously evaluate and refine the technology behind VP.S ENCORE®.
• 01
Every viable heart. Every viable recipient.
More than 100,000 patients are awaiting transplant — yet only a fraction of available donor hearts ever reach the operating room. The gap is not one of medicine; it is one of time, logistics, and preservation science.
We built Vascular Perfusion Solutions on a stubborn belief: the simplest tool is the one that reaches the most patients. Cardiac graft preservation is an engineering problem, a logistics problem, and a workflow problem — and a simpler, bloodless system is the quieter design decision that scales.
Saving Organs. Saving Lives.
• 02
Simplicity, rigorously earned.
Scientific collaboration
Ongoing partnerships with leading cardiac centers, government institutions, and academic labs — in organ preservation, pediatric work, kidney preservation, and gene delivery.
Practical innovation
Technology that integrates into existing workflows. Familiar, standardized materials. No specialty reagents, no blood products, no re-engineered retrieval protocols.
• 03
Where we've been. Where we're going.
Founded
Vascular Perfusion Solutions established
A Texas-based MedTech company founded to advance cardiac graft preservation through simplified hypothermic machine perfusion.
Phase I
First preclinical perfusions
Initial bench and animal-model evaluation of the VP.S ENCORE® circuit — bloodless, passively cooled, FDA-approved perfusate.
100+
Preclinical milestone reached
More than 100 heart perfusions completed, informing successive refinements to the circuit and materials.
FDA
Breakthrough Device Designation
Recognition from the FDA for a technology addressing an unmet medical need.
Today
Ongoing clinical development
Research partnerships expanding into pediatric heart preservation, kidney preservation, gene delivery during perfusion, and vascularized composite tissue preservation.
• 04
Research in company.
VPS works with leading cardiac centers, government institutions, and academic partners across organ preservation science.
Duke University
UT Health San Antonio
Texas Heart Institute
Department of Defense
ARPA-H
Wyss Institute
Duke University
UT Health San Antonio
Texas Heart Institute
Department of Defense
ARPA-H
Wyss Institute
• 05
The team behind VP.S ENCORE®.
LT
Leadership Team Member
CEO & Co-FounderLeads company strategy, clinical development priorities, and the commercial roadmap for VP.S ENCORE®.
LT
Leadership Team Member
Chief Medical OfficerOversees preclinical and clinical research, publications, and collaboration with transplant centers and academic partners.
LT
Leadership Team Member
Chief Technology OfficerDirects engineering, circuit design, and the continuous refinement of the VP.S ENCORE® perfusion platform.